Skip to main content

Advertisement

SpringerLink
Log in

Withdrawing Benzodiazepines in Patients With Anxiety Disorders

  • Anxiety Disorders (A Pelissolo, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

The large class of CNS-depressant medications—the benzodiazepines—have been extensively used for over 50 years, anxiety disorders being one of the main indications. A substantial proportion (perhaps up to 20–30 %) of long-term users becomes physically dependent on them. Problems with their use became manifest, and dependence, withdrawal difficulties and abuse were documented by the 1980s. Many such users experience physical and psychological withdrawal symptoms on attempted cessation and may develop clinically troublesome syndromes even during slow tapering. Few studies have been conducted to establish the optimal withdrawal schedules. The usual management comprises slow withdrawal over weeks or months together with psychotherapy of various modalities. Pharmacological aids include antidepressants such as the SSRIs especially if depressive symptoms supervene. Other pharmacological agents such as the benzodiazepine antagonist, flumazenil, and the hormonal agent, melatonin, remain largely experimental. The purpose of this review is to analyse the evidence for the efficacy of the usual withdrawal regimes and the newer agents. It is concluded that little evidence exists outside the usual principles of drug withdrawal but there are some promising leads.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. D’Hulst C, Atack J, Kooy R. The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov Today. 2009;14(17–18):866–75.

    Article  PubMed  Google Scholar 

  2. Lader M. Benzodiazepines revisited-will we ever learn? Addiction. 2011;106(12):2086–109.

    Article  PubMed  Google Scholar 

  3. O’Brien C. Benzodiazepine use, abuse and dependence. J Clin Psychiatry. 2005;66:28–33.

    Article  PubMed  Google Scholar 

  4. Donoghue J, Lader M. Usage of benzodiazepines: a review. Int J Psychiatry Clin Pract. 2010;14(2):78–87.

    Article  CAS  PubMed  Google Scholar 

  5. Locke A, Kirst N, Shultz C. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2015;91:617–24.

    PubMed  Google Scholar 

  6. Cloos J, Ferreira V. Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry. 2009;22(1):90–5.

    Article  PubMed  Google Scholar 

  7. Baldwin D, Aitchison K, Bateson A, Curran H, Davies S, Leonard B, et al. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol. 2013;27(11):967–71. A reconsideration of the risk/benefit of benzodiazepines.

    Article  CAS  PubMed  Google Scholar 

  8. Rcpsych.ac.uk. Benzodiazepines [Internet]. 2015 [cited 19 June 2015]. Available from: http://www.rcpsych.ac.uk/healthadvice/treatmentswellbeing/benzodiazepines.aspx.

  9. Mehdi T. Benzodiazepines revisited. Br J Med Pract Manage. 2012;5(1):a501.

    CAS  Google Scholar 

  10. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005;18(3):249–55.

    Article  PubMed  Google Scholar 

  11. Petursson H, Lader M. Dependence on tranquillizers. Oxford: Oxford University Press; 1984.

    Google Scholar 

  12. Tvete I, Bjorner T, Aursnes I, Skomedal T. A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. BMJ Open. 2013;3(10):e003296.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Vinkers C, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharm Sci. 2012;2012:1–19.

    Article  Google Scholar 

  14. Manthey L, Lohbeck M, Giltay E, van Veena T, Zitman F, Penninx B. Correlates of benzodiazepine dependence in the Netherlands study of depression and anxiety. Addiction. 2012;107(12):2173–82. Presents predictive data on dependence liability.

    Article  PubMed  Google Scholar 

  15. Cuevas C, Sanz E, Fuente J, Padilla J, Berenguer J. The severity of dependence scale (SDS) as screening test for benzodiazepine dependence: SDS validation study. Addiction. 2000;95(2):245–50.

    Article  PubMed  Google Scholar 

  16. Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand. 1998;98(s393):95–101.

    Article  Google Scholar 

  17. Higgitt A, Fonagy P, Toone B, Shine P. The prolonged benzodiazepine withdrawal syndrome: anxiety or hysteria? Acta Psychiatr Scand. 1990;82(2):165–8.

    Article  CAS  PubMed  Google Scholar 

  18. Hallstrom C, Lader M. Benzodiazepine withdrawal phenomena. Int Pharmacopsychiatry. 1981;16:235–44.

    CAS  PubMed  Google Scholar 

  19. Lader M. Long-term anxiolytic therapy: the issue of drug withdrawal. J Clin Psychiatry. 1987;1(48 Suppl):12–6.

    Google Scholar 

  20. Vikander B, Koechling U, Borg S, Tönne U, Hiltunen A. Benzodiazepine tapering: a prospective study. Nord J Psychiatry. 2010;64(4):273–82.

    Article  PubMed  Google Scholar 

  21. Russell J, Lader M. Guidelines for the prevention and treatment of benzodiazepine dependence. London: The Mental Health Foundation; 1994.

    Google Scholar 

  22. Mcgregor C, Machin A, White J. In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods. Drug Alcohol Rev. 2003;22(2):175–80.

    Article  PubMed  Google Scholar 

  23. Kan C, Breteler M, Zitman F. High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria. Acta Psychiatr Scand. 1997;96(2):85–93.

    Article  CAS  PubMed  Google Scholar 

  24. de Gier N, Gorgels W, Lucassen P, Oude Voshaar R, Mulder J, Zitman F. Discontinuation of long-term benzodiazepine use: 10-year follow-up. Fam Pract. 2010;28(3):253–9.

    Article  PubMed  Google Scholar 

  25. Lingford-Hughes A, Welch S, Peters L, Nutt D. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol. 2012;26(7):899–952. An authoritative review on the features and management of various types of addiction.

    Article  CAS  PubMed  Google Scholar 

  26. Ashton C. Benzodiazepines: how they work & how to withdraw. Newcastle: University of Newcastle; 2001.

    Google Scholar 

  27. Higgitt A, Lader M, Fonagy P. Clinical management of benzodiazepine dependence. BMJ. 1985;291(6503):1202.

    Article  PubMed Central  Google Scholar 

  28. Voshaar R. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189(3):213–20.

    Article  PubMed  Google Scholar 

  29. Denis D, Fatseas M, Lavie E, Auriscombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev. 2007. CD005194.

  30. Murphy S, Tyrer P. A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. Br J Psychiatry. 1991;158(4):511–6.

  31. Voshaar R, Gorgels W, Mol A, Van Balkom A, Mulder J, Van De Lisdonk E, et al. Long-term outcome of two forms of randomised benzodiazepine discontinuation. Br J Psychiatry. 2006;188(2):188–9.

    Article  Google Scholar 

  32. Podhorna J. The experimental pharmacotherapy of benzodiazepine withdrawal. Curr Pharm Des. 2002;8(1):23–43.

    Article  CAS  PubMed  Google Scholar 

  33. Sullivan M, Toshima M, Lynn P, Roy-Byrne P. Phenobarbital versus clonazepam for sedative-hypnotic taper in chronic pain patients: a pilot study. Ann Clin Psychiatry. 1993;5(2):123–8.

    Article  CAS  PubMed  Google Scholar 

  34. Kawasaki S, Jacapraro J, Rastegar D. Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification. J Subst Abus Treat. 2012;43(3):331–4.

    Article  Google Scholar 

  35. Schweizer E. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Arch Gen Psychiatry. 1991;48(5):448.

    Article  CAS  PubMed  Google Scholar 

  36. Efficacy of drug treatments for Generalised Anxiety Disorder: systematic review and meta-analysis. BMJ. 2011;342(mar16 2):d1718-d1718.

  37. Baldwin D, Anderson I, Nutt D, Allgulander C, Bandelow B, den Boer J, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–39. An authoritative survey of the treatments available to treat various anxiety disorders.

    Article  PubMed  Google Scholar 

  38. Baldwin D, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2007;3(2):185–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Hadley S, Mandel F, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2011;26(4):461–70.

    Article  PubMed  Google Scholar 

  40. Crockford D, White W, Campbell B. Gabapentin use in benzodiazepine dependence and detoxification. Can J Psychiatr. 2001;46:287.

    CAS  Google Scholar 

  41. Chessick C, Allen M, Thase M. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2015;3, CD006115.

    Google Scholar 

  42. Ashton C, Rawlins M, Tyrer S. A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry. 1990;157(2):232–8.

    Article  CAS  PubMed  Google Scholar 

  43. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010;12. CD006815.

  44. Gao K, Sheehan D, Calabrese J. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother. 2009;9(8):1147–58.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Vulink N, Figee M, Denys D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol. 2011;21(6):429–49.

    Article  CAS  PubMed  Google Scholar 

  46. Srinivasan V, Brzezinski A, Pandi-Perumal S, Spence D, Cardinali D, Brown G. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(4):913–23.

    Article  CAS  Google Scholar 

  47. Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin. Arch Intern Med. 1999;159(20):2456.

    Article  CAS  PubMed  Google Scholar 

  48. Peles E, Hetzroni T, Bar-Hamburger R, Adelson M, Schreiber S. Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial. Addiction. 2007;102(12):1947–53.

    Article  PubMed  Google Scholar 

  49. Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries. Eur J Clin Pharmacol. 2012;69(4):1–10.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Rickels K, DeMartinis N, Rynn M, Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 1999;19:12S–6S.

    Article  CAS  PubMed  Google Scholar 

  51. Tyrer P, Ferguson B, Hallstrom C, Michie M, Tyrer S, Cooper S, et al. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. Br J Psychiatry. 1996;168(4):457–61.

    Article  CAS  PubMed  Google Scholar 

  52. Zitman FG, Couveé JE. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off. Report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry. 2001;178(4):317–24.

    Article  CAS  PubMed  Google Scholar 

  53. Nakao M, Takeuchi T, Nomura K, Teramoto T, Yano E. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. Psychiatry Clin Neurosci. 2006;60(5):605–10.

    Article  CAS  PubMed  Google Scholar 

  54. Spiegel D. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 1999;19:17S–22S.

    Article  CAS  PubMed  Google Scholar 

  55. Voshaar R, Gorgels W, Mol A, Van Balkom A, Van de Lisdonk E, Breteler M, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. Br J Psychiatry. 2003;182(6):498–504.

    Article  PubMed  Google Scholar 

  56. Gosselin P, Ladouceur R, Morin C, Dugas M, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006;74(5):908–19.

    Article  PubMed  Google Scholar 

  57. Baillargeon L, Landreville P, Verreault R, Beauchemin J, Gregoire J, Morin C. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering; a randomized trial. Can Med Assoc J. 2003;169:1015–20.

    Google Scholar 

  58. Ten Wolde G, Dijkstra A, van Empelen P, van den Hout W, Knuistingh Neven A, Zitman F. Long-term effectiveness of computer-generated tailored patient education on benzodiazepines: a randomized controlled trial. Addiction. 2008;103(4):662–70.

    Article  PubMed  Google Scholar 

  59. Parr J, Kavanagh D, Cahill L, Mitchell G, Young R. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction. 2009;104(1):13–24.

    Article  PubMed  Google Scholar 

  60. Smith A, Tett S. Improving the use of benzodiazepines—is it possible? A non-systematic review of interventions tried in the last 20 years. BMC Health Serv Res. 2010;10(1):321.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Gould R, Coulson M, Patel N, Highton-Williamson E, Howard R. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204(2):98–107.

    Article  PubMed  Google Scholar 

  62. Hood S, Norman A, Hince D, Melichar J, Hulse G. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol. 2014;77(2):285–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Gerra G, Giucasto G, Zaimovic A, Fertonani G, Chittolini B, Avanzini P, et al. Intravenous flumazenil following prolonged exposure to lormetazepam in humans: lack of precipitated withdrawal. Int Clin Psychopharmacol. 1996;11(2):81–8.

    CAS  PubMed  Google Scholar 

  64. Griffiths R, Evans S, Guarino J. Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: antagonism and precipitated withdrawal. J Pharmacol Exp Ther. 1993;265:1163–74.

    CAS  PubMed  Google Scholar 

  65. Mintzer M, Stoller K, Griffiths R. A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users. Psychopharmacology. 1999;147(2):200–9.

    Article  CAS  PubMed  Google Scholar 

  66. Lader M, Morton S. A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. J Psychopharmacol. 1992;6(3):357–63.

    Article  CAS  PubMed  Google Scholar 

  67. Saxon L, Hjemdahl P, Hiltunen A, Borg S. Effects of flumazenil in the treatment of benzodiazepine withdrawal—a double-blind pilot study. Psychopharmacology. 1997;131(2):153–60.

    Article  CAS  PubMed  Google Scholar 

  68. Gerra G, Zaimovic A, Giusti F, Moi G, Brewer C. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study. Addict Biol. 2002;7(4):385–95.

  69. Hood S, O’Neil G, Hulse G. The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. J Psychopharmacol. 2009;23(4):401–9.

    Article  CAS  PubMed  Google Scholar 

  70. Quaglio G, Pattaro C, Gerra G, Mathewson S, Verbanck P, Des Jarlais D, et al. High dose benzodiazepine dependence: description of 29 patients treated with flumazenil infusion and stabilised with clonazepam. Psychiatry Res. 2012;198(3):457–62.

    Article  CAS  PubMed  Google Scholar 

  71. Hulse G, O’Neil G, Morris N, Bennett K, Norman A, Hood S. Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series. J Psychopharmacol. 2012;27(2):222–7.

    Article  PubMed  Google Scholar 

  72. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23(1):19.

    Article  CAS  PubMed  Google Scholar 

  73. Parr J, Kavanagh D, Young R, Mitchell G. Acceptability of cognitive-behaviour therapy via the internet for cessation of benzodiazepine use. Drug Alcohol Rev. 2011;30(3):306–14.

    Article  PubMed  Google Scholar 

  74. Vorma H, Naukkarinen H, Sarna S, Kuoppasalmi K. Treatment of out-patients with complicated benzodiazepine dependence: comparison of two approaches. Addiction. 2002;97(7):851–9.

    Article  PubMed  Google Scholar 

  75. Lugoboni F, Quaglio G. Exploring the dark side of the moon: the treatment of benzodiazepine tolerance. Br J Clin Pharmacol. 2014;77(2):239–41. An expert account of the management of benzodiazepine dependence and withdrawal.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. Barker M. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004;19(3):437–54.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neurosciences, King’s College London, Denmark Hill, London, SE5 8AF, UK

    Malcolm Lader & Andri Kyriacou

Authors
  1. Malcolm Lader
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andri Kyriacou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malcolm Lader.

Ethics declarations

Conflict of Interest

Malcolm Lader and Andri Kyriacou declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Anxiety Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lader, M., Kyriacou, A. Withdrawing Benzodiazepines in Patients With Anxiety Disorders. Curr Psychiatry Rep 18, 8 (2016). https://doi.org/10.1007/s11920-015-0642-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-015-0642-5

Keywords

Search

Navigation